Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

The tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR), such as osimertinib and gefitinib, aumolertinib have been widely used in EGFR mutation‐positive non‐small cell lung cancer (NSCLC) patients. However, the discrepancy of pharmacokinetic features and distributions in imp...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	MedComm - Oncology 2024-12, Vol.3 (4)
Hauptverfasser:	Ren, Ran, Zhang, Jiangang, He, Yongpeng, Zeng, Xianghua, Zhou, Yu, Shen, Luyao, Li, Yongsheng, Li, Dairong, Zhao, Huakan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!